Clinical diagnosis and staging of cholangiocarcinoma - Nature Reviews Gastroenterology & Hepatology
- ️Gores, Gregory J.
- ️Tue Aug 02 2011
Everhart, J. E. & Ruhl, C. E. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology 136, 1134–1144 (2009).
DeOliveira, M. L. et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53, 1363–1371 (2011).
DeOliveira, M. L. et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245, 755–762 (2007).
Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R. & Pfeiffer, R. M. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J. Natl Cancer Inst. 98, 873–875 (2006).
Burak, K. et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. 99, 523–526 (2004).
Yamasaki, S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J. Hepatobiliary Pancreat. Surg. 10, 288–291 (2003).
Nathan, H. et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 16, 14–22 (2009).
Sasaki, A. et al. Intrahepatic peripheral cholangiocarcinoma: mode of spread and choice of surgical treatment. Br. J. Surg. 85, 1206–1209 (1998).
Shimada, K. et al. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J. Surg. 31, 2016–2022 (2007).
Yamamoto, Y. et al. Clinicopathological characteristics of intrahepatic cholangiocellular carcinoma presenting intrahepatic bile duct growth. J. Surg. Oncol. 99, 161–165 (2009).
Farges, O. et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 117, 2170–2177 (2010).
El Rassi, Z. E. et al. Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management. Eur. J. Surg. Oncol. 25, 375–380 (1999).
Torzilli, G. et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30, 889–893 (1999).
Blechacz, B. & Gores, G. J. Positron emission tomography scan for a hepatic mass. Hepatology 52, 2186–2191 (2010).
Vilgrain, V. et al. Intrahepatic cholangiocarcinoma: MRI and pathologic correlation in 14 patients. J. Comput. Assist. Tomogr. 21, 59–65 (1997).
Braga, H. J., Imam, K. & Bluemke, D. A. MR imaging of intrahepatic cholangiocarcinoma: use of ferumoxides for lesion localization and extension. AJR Am. J. Roentgenol. 177, 111–114 (2001).
Raman, S. S. et al. Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases. AJR Am. J. Roentgenol. 177, 807–812 (2001).
Rimola, J. et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 50, 791–798 (2009).
Vilgrain, V. Staging cholangiocarcinoma by imaging studies. HPB (Oxford) 10, 106–109 (2008).
Corvera, C. U. et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J. Am. Coll. Surg. 206, 57–65 (2008).
Tao, L. Y., Cai, L., He, X. D., Liu, W. & Qu, Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am. Surg. 76, 1210–1213 (2010).
Uenishi, T. et al. Cytokeratin-19 fragments in serum (CYFRA 21–1) as a marker in primary liver cancer. Br. J. Cancer 88, 1894–1899 (2003).
Uenishi, T. et al. Serum cytokeratin 19 fragment (CYFRA21–1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 15, 583–589 (2008).
Nakanuma, Y. et al. Intrahepatic cholangiocarcinoma. 217–224 (International Agency for Research on Cancer [IARC], Lyon, 2010).
Desmet, V., Roskams, T. & De Vos, R. Normal Anatomy in Gastroenterology and Hepatology. The Comprehensive Visual Reference (ed. LaRusso, N. F.) 1.14 (Current Medicine, Philadelphia, 1997).
Nakanuma, Y., Hoso, M., Sanzen, T. & Sasaki, M. Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc. Res. Tech. 38, 552–570 (1997).
Komuta, M. et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47, 1544–1556 (2008).
Asayama, Y. et al. Imaging of cholangiolocellular carcinoma of the liver. Eur. J. Radiol. 75, e120–e125 (2010).
Motosugi, U. et al. Cholangiolocellular carcinoma of the liver: imaging findings. J. Comput. Assist. Tomogr. 33, 682–688 (2009).
Rullier, A. et al. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am. J. Surg. Pathol. 24, 870–876 (2000).
Maeda, T. et al. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod. Pathol. 9, 901–909 (1996).
Vilana, R. et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51, 2020–2029 (2010).
Sapisochin, G., Fidelman, N., Roberts, J. P. & Yao, F. Y. Mixed hepatocellular-cholangiocarcinoma (HCC-CC) and intra-hepatic cholangiocarcinoma (I-CC) in patients transplanted for hepatocellular carcinoma. Liver Transpl. doi:10.1002/lt.22307.
Yamashita, Y., Takahashi, M., Kanazawa, S., Charnsangavej, C. & Wallace, S. Hilar cholangiocarcinoma. An evaluation of subtypes with CT and angiography. Acta Radiol. 33, 351–355 (1992).
Alden, M. E. et al. Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct. Radiology 197, 511–516 (1995).
Johnson, S. R., Kelly, B. S., Pennington, L. J. & Hanto, D. W. A single center experience with extrahepatic cholangiocarcinomas. Surgery 130, 584–590 (2001).
Heron, D. E. et al. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am. J. Clin. Oncol. 26, 422–428 (2003).
Blechacz, B. & Gores, G. J. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48, 308–321 (2008).
Nagorney, D. M., Donohue, J. H., Farnell, M. B., Schleck, C. D. & Ilstrup, D. M. Outcomes after curative resections of cholangiocarcinoma. Arch. Surg. 128, 871–877 (1993).
Hann, L. E. et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am. J. Roentgenol. 167, 1017–1021 (1996).
Nakeeb, A. et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224, 463–473 (1996).
Ghazale, A. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134, 706–715 (2008).
Akdogan, M. et al. Extraordinarily elevated CA19–9 in benign conditions: a case report and review of the literature. Tumori 87, 337–339 (2001).
Levy, C. et al. The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50, 1734–1740 (2005).
Patel, A. H., Harnois, D. M., Klee, G. G., LaRusso, N. F. & Gores, G. J. The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am. J. Gastroenterol. 95, 204–207 (2000).
Vestergaard, E. M. et al. Reference values and biological variation for tumor marker CA 19–9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin. Chem. 45, 54–61 (1999).
Feydy, A. et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am. J. Roentgenol. 172, 73–77 (1999).
Lee, H. Y. et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology 239, 113–121 (2006).
Aloia, T. A. et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am. J. Surg. 193, 702–706 (2007).
Tillich, M., Mischinger, H. J., Preisegger, K. H., Rabl, H. & Szolar, D. H. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am. J. Roentgenol. 171, 651–658 (1998).
Kato, T. et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur. J. Nucl. Med. Mol. Imaging 29, 1047–1054 (2002).
Lopera, J. E., Soto, J. A. & Munera, F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 220, 90–96 (2001).
Manfredi, R., Barbaro, B., Masselli, G., Vecchioli, A. & Marano, P. Magnetic resonance imaging of cholangiocarcinoma. Semin. Liver Dis. 24, 155–164 (2004).
Masselli, G., Manfredi, R., Vecchioli, A. & Gualdi, G. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. Eur. Radiol. 18, 2213–2221 (2008).
Vogl, T. J. et al. Staging of Klatskin tumours (hilar cholangiocarcinomas): comparison of MR cholangiography, MR imaging, and endoscopic retrograde cholangiography. Eur. Radiol. 16, 2317–2325 (2006).
Kluge, R. et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33, 1029–1035 (2001).
Hattori, M. et al. Prospective study of biliary cytology in suspected perihilar cholangiocarcinoma. Br. J. Surg. 98, 704–709 (2011).
Halling, K. C. & Kipp, B. R. Fluorescence in situ hybridization in diagnostic cytology. Hum. Pathol. 38, 1137–1144 (2007).
DeHaan, R. D. et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum. Pathol. 38, 491–499 (2007).
Lee, M., Banerjee, S., Posner, M. C. & Cartwright, C. A. Distal extrahepatic cholangiocarcinoma presenting as cholangitis. Dig. Dis. Sci. 55, 1852–1855 (2010).
Sobin, L. H. TNM: principles, history, and relation to other prognostic factors. Cancer 91, 1589–1592 (2001).
Choi, S. B. et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann. Surg. Oncol. 16, 3048–3056 (2009).
Tamandl, D. et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br. J. Surg. 96, 919–925 (2009).
Endo, I. et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 248, 84–96 (2008).
Shen, W. F. et al. Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J. Gastroenterol. 15, 5976–5982 (2009).
Weber, S. M. et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J. Am. Coll. Surg. 193, 384–391 (2001).
Uchiyama, K. et al. Impact of nodal involvement on surgical outcomes of intrahepatic cholangiocarcinoma: a multicenter analysis by the Study Group for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J. Hepatobiliary Pancreat. Sci. 18, 443–452 (2011).
Okabayashi, T. et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 92, 2374–2383 (2001).
Farges, O. et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 117, 2170–2177 (2011).
Uenishi, T. et al. Serosal invasion in TNM staging of mass-forming intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Surg. 12, 479–483 (2005).
Sotiropoulos, G. C. et al. Multicentric evaluation of a clinical and prognostic scoring system predictive of survival after resection of intrahepatic cholangiocarcinomas. Liver Int. 30, 996–1002 (2010).
Ito, K. et al. Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma. Ann. Surg. 251, 675–681 (2010).
Klempnauer, J. et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J. Clin. Oncol. 15, 947–954 (1997).
Ramacciato, G. et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am. Surg. 76, 1260–1268 (2010).
Fernandez-Ruiz, M., Guerra-Vales, J. M. & Colina-Ruizdelgado, F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J. Gastroenterol. 15, 5279–5286 (2009).
Park, J. et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3, 298–305 (2009).
Heimbach, J. K. et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 82, 1703–1707 (2006).
Bismuth, H. & Corlette, M. B. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet. 140, 170–178 (1975).
Bismuth, H., Nakache, R. & Diamond, T. Management strategies in resection for hilar cholangiocarcinoma. Ann. Surg. 215, 31–38 (1992).
Zervos, E. E. et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am. J. Surg. 190, 810–815 (2005).
Jarnagin, W. R. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 234, 507–517 (2001).
Ebata, T. et al. The concept of perihilar cholangiocarcinoma is valid. Br. J. Surg. 96, 926–934 (2009).
Sano, T. et al. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann. Surg. Oncol. 15, 590–599 (2008).
Blechacz, B. R., Sanchez, W. & Gores, G. J. A conceptual proposal for staging ductal cholangiocarcinoma. Curr. Opin. Gastroenterol. 25, 238–239 (2009).
Ito, F. et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann. Surg. 248, 273–279 (2008).
Guglielmi, A. et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J. Surg. 33, 1247–1254 (2009).
Nagino, M. Perihilar cholangiocarcinoma: a much needed but imperfect new staging system. Nat. Rev. Gastroenterol. Hepatol. 8, 252–253 (2010).
Sakamoto, Y. et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137, 396–402 (2005).
Hong, S. M. et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 146, 250–257 (2009).
Murakami, Y. et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J. Surg. Oncol. 95, 207–212 (2007).
Woo, S. M. et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 14, 3195–3201 (2007).
Yoshida, T. et al. Lymphatic spread differs according to tumor location in extrahepatic bile duct cancer. Hepatogastroenterology 50, 17–20 (2003).
Murakami, Y. et al. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J. Surg. 31, 337–342 (2007).
Yoshida, T. et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch. Surg. 137, 69–73 (2002).
Ebata, T. et al. Pancreatic and duodenal invasion in distal bile duct cancer: paradox in the tumor classification of the American Joint Committee on Cancer. World J. Surg. 31, 2008–2015 (2007).